Pharmaceutical combination
AssigneeAltherx, Inc.
InventorsStephen Caltabiano, Eliot Ohlstein, Stewart Mccallum
Life of this patent
Estimating the term…
Abstract
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
Claims30
A synergistic combination for relieving one or more symptoms associated with overactive bladder (OAB) comprising:
- (i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist;
- and
- (ii) a therapeutically effective amount, or a sub-therapeutically effective amount of a muscarinic receptor antagonist.
A synergistic combination for relieving one or more symptoms associated with overactive bladder (OAB) comprising:
- (i) a therapeutically effective amount of solabegron, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt solvated with pharmaceutically acceptable solvent thereof;
- and
- (ii) a therapeutically effective amount, or a sub-therapeutically effective amount of tolterodine, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt solvated with pharmaceutically acceptable solvent thereof.
A method of treating one or more symptoms associated with overactive bladder in a mammal, comprising administering to said mammal:
- (i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist;
- and
- (ii) a therapeutically effective amount, a sub-therapeutically effective amount of a muscarinic receptor antagonist.
A method of treating one or more symptoms associated with overactive bladder in a mammal, comprising administering to said mammal:
- (i) a therapeutically effective amount of solabegron, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt solvated with pharmaceutically acceptable solvent thereof;
- and
- (ii) a therapeutically effective amount, or a sub-therapeutically effective amount of tolterodine, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt solvated with pharmaceutically acceptable solvent thereof.
Dependencies are inferred from the claim text.